strides pharma uk ltd
strides pharma uk ltd Company Information
Company Number
02882063
Website
http://www.strides.comRegistered Address
unit 4 the metro centre, dwight road, watford, WD18 9SS
Industry
Manufacture of basic pharmaceutical products
Telephone
01923255580
Next Accounts Due
December 2025
Group Structure
View All
Shareholders
strides pharma global (uk) 100%
strides pharma uk ltd Estimated Valuation
Pomanda estimates the enterprise value of STRIDES PHARMA UK LTD at £49.7m based on a Turnover of £28.7m and 1.73x industry multiple (adjusted for size and gross margin).
strides pharma uk ltd Estimated Valuation
Pomanda estimates the enterprise value of STRIDES PHARMA UK LTD at £23.2m based on an EBITDA of £3m and a 7.78x industry multiple (adjusted for size and gross margin).
strides pharma uk ltd Estimated Valuation
Pomanda estimates the enterprise value of STRIDES PHARMA UK LTD at £22.7m based on Net Assets of £8.9m and 2.56x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Strides Pharma Uk Ltd Overview
Strides Pharma Uk Ltd is a live company located in watford, WD18 9SS with a Companies House number of 02882063. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in December 1993, it's largest shareholder is strides pharma global (uk) with a 100% stake. Strides Pharma Uk Ltd is a mature, large sized company, Pomanda has estimated its turnover at £28.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Strides Pharma Uk Ltd Health Check
Pomanda's financial health check has awarded Strides Pharma Uk Ltd a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 8 areas for improvement. Company Health Check FAQs
2 Strong
2 Regular
8 Weak
Size
annual sales of £28.7m, make it in line with the average company (£30.8m)
£28.7m - Strides Pharma Uk Ltd
£30.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 9%, show it is growing at a faster rate (6.4%)
9% - Strides Pharma Uk Ltd
6.4% - Industry AVG
Production
with a gross margin of 25.9%, this company has a higher cost of product (39.3%)
25.9% - Strides Pharma Uk Ltd
39.3% - Industry AVG
Profitability
an operating margin of 8% make it as profitable than the average company (9.5%)
8% - Strides Pharma Uk Ltd
9.5% - Industry AVG
Employees
with 24 employees, this is below the industry average (125)
24 - Strides Pharma Uk Ltd
125 - Industry AVG
Pay Structure
on an average salary of £108k, the company has a higher pay structure (£57.4k)
£108k - Strides Pharma Uk Ltd
£57.4k - Industry AVG
Efficiency
resulting in sales per employee of £1.2m, this is more efficient (£330.3k)
£1.2m - Strides Pharma Uk Ltd
£330.3k - Industry AVG
Debtor Days
it gets paid by customers after 89 days, this is later than average (65 days)
89 days - Strides Pharma Uk Ltd
65 days - Industry AVG
Creditor Days
its suppliers are paid after 7 days, this is quicker than average (34 days)
7 days - Strides Pharma Uk Ltd
34 days - Industry AVG
Stock Days
it holds stock equivalent to 218 days, this is more than average (96 days)
218 days - Strides Pharma Uk Ltd
96 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (10 weeks)
0 weeks - Strides Pharma Uk Ltd
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 69.5%, this is a higher level of debt than the average (36.5%)
69.5% - Strides Pharma Uk Ltd
36.5% - Industry AVG
STRIDES PHARMA UK LTD financials
Strides Pharma Uk Ltd's latest turnover from March 2024 is £28.7 million and the company has net assets of £8.9 million. According to their latest financial statements, Strides Pharma Uk Ltd has 24 employees and maintains cash reserves of £85.6 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 28,687,503 | 24,544,791 | 19,069,031 | 22,368,976 | 19,671,834 | 10,426,208 | 6,543,000 | 4,724,000 | 3,212,000 | ||||||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Cost Of Sales | 21,245,901 | 18,690,393 | 15,964,699 | 16,356,868 | 13,476,434 | 6,197,536 | 6,901,000 | 3,922,000 | 2,856,000 | ||||||
| Gross Profit | 7,441,602 | 5,854,398 | 3,104,332 | 6,012,108 | 6,195,400 | 4,228,672 | -358,000 | 802,000 | 356,000 | ||||||
| Admin Expenses | 5,149,561 | 4,688,222 | 5,521,325 | 3,212,714 | 2,458,859 | 1,164,321 | 965,000 | 1,110,000 | 1,004,000 | ||||||
| Operating Profit | 2,292,041 | 1,166,176 | -2,416,993 | 2,799,394 | 3,736,541 | 3,064,351 | -1,323,000 | -308,000 | -648,000 | ||||||
| Interest Payable | 1,009,537 | 301,967 | 264,989 | 670,615 | 141,922 | 31,623 | 56,000 | 46,000 | 0 | ||||||
| Interest Receivable | 17 | 39,712 | 48,337 | 46,948 | 25,431 | 0 | 0 | 2,000 | |||||||
| Pre-Tax Profit | 1,282,521 | 903,921 | -2,633,645 | 2,175,727 | 3,620,050 | 3,033,249 | -1,379,000 | -354,000 | -659,000 | ||||||
| Tax | -444,632 | -234,152 | 316,833 | -127,244 | -383,356 | -24,038 | 0 | 0 | 0 | ||||||
| Profit After Tax | 837,889 | 669,769 | -2,316,812 | 2,048,483 | 3,236,694 | 3,009,211 | -1,379,000 | -354,000 | -659,000 | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 2,001,600 | 0 | 0 | 0 | 0 | ||||||
| Retained Profit | 837,889 | 669,769 | -2,316,812 | 2,048,483 | 1,235,094 | 3,009,211 | -1,379,000 | -354,000 | -659,000 | ||||||
| Employee Costs | 2,592,258 | 1,883,613 | 2,319,279 | 1,047,423 | 698,186 | 436,274 | 352,000 | 342,000 | 292,000 | ||||||
| Number Of Employees | 24 | 23 | 21 | 15 | 11 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | |||
| EBITDA* | 2,983,064 | 1,973,517 | -1,722,360 | 3,604,423 | 3,884,406 | 3,118,487 | -1,098,000 | -79,000 | -458,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 398,443 | 329,573 | 422,920 | 510,367 | 711,691 | 606,482 | 620,400 | 331,370 | 323,405 | 325,696 | 322,451 | 325,142,000 | 329,359,000 | 334,000 | 343,000 |
| Intangible Assets | 8,051,797 | 4,917,520 | 5,509,825 | 6,073,136 | 6,371,007 | 182,623 | 7,312 | 13,580 | 20,320 | 64,348 | 93,234 | 242,316,000 | 467,477,000 | 685,000 | 872,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 8,450,240 | 5,247,093 | 5,932,745 | 6,583,503 | 7,082,698 | 789,105 | 627,712 | 344,950 | 343,725 | 390,044 | 415,685 | 567,458,000 | 796,836,000 | 1,019,000 | 1,215,000 |
| Stock & work in progress | 12,736,275 | 11,620,700 | 19,926,314 | 7,290,454 | 3,837,402 | 2,206,622 | 1,893,444 | 2,596,432 | 2,319,154 | 2,147,633 | 1,530,856 | 1,810,302,000 | 2,890,595,000 | 1,423,000 | 714,000 |
| Trade Debtors | 7,012,132 | 7,493,227 | 4,022,503 | 4,036,062 | 4,646,462 | 3,143,397 | 1,456,924 | 1,523,859 | 1,400,732 | 1,537,922 | 1,082,176 | 1,283,675,000 | 941,466,000 | 569,000 | 673,000 |
| Group Debtors | 0 | 29,018 | 1,211,887 | 1,729,370 | 3,351,744 | 1,194,060 | 669,478 | 409,024 | 389,024 | 0 | 0 | 0 | 0 | 0 | 32,000 |
| Misc Debtors | 813,733 | 1,428,863 | 411,737 | 409,330 | 1,203,846 | 61,063 | 68,933 | 74,513 | 231,590 | 0 | 0 | 0 | 0 | 117,000 | 195,000 |
| Cash | 85,598 | 118,105 | 2,532,036 | 1,191,411 | 960,166 | 97,017 | 224,476 | 98,975 | 360,949 | 11,427 | 92,798 | 67,000 | 0 | 0 | 7,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 20,647,738 | 20,689,913 | 28,104,477 | 14,656,627 | 13,999,620 | 6,702,159 | 4,313,255 | 4,702,803 | 4,701,449 | 3,696,982 | 2,705,830 | 3,094,044,000 | 3,832,061,000 | 2,109,000 | 1,621,000 |
| total assets | 29,097,978 | 25,937,006 | 34,037,222 | 21,240,130 | 21,082,318 | 7,491,264 | 4,940,967 | 5,047,753 | 5,045,174 | 4,087,026 | 3,121,515 | 3,661,502,000 | 4,628,897,000 | 3,128,000 | 2,836,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 149,753 | 0 | 0 | 0 | 0 | 0 | 128,000 | 0 |
| Bank loan | 2,933,839 | 3,645,956 | 0 | 1,571,000 | 6,543,414 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 413,172 | 246,480 | 24,989,064 | 235,485 | 96,154 | 154,999 | 93,232 | 114,708 | 295,293 | 1,327,242 | 1,186,752 | 2,303,341,000 | 4,463,829,000 | 258,000 | 532,000 |
| Group/Directors Accounts | 5,344,483 | 12,086,268 | 0 | 5,465,719 | 1,294,071 | 216,074 | 1,326,411 | 1,542,833 | 844,336 | 0 | 0 | 0 | 0 | 1,664,000 | 1,186,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,010,831 | 1,916,339 | 0 | 977,684 | 594,622 | 679,635 | 90,139 | 352,048 | 295,287 | 0 | 0 | 0 | 0 | 113,000 | 78,000 |
| total current liabilities | 10,702,325 | 17,895,043 | 24,989,064 | 8,249,888 | 8,528,261 | 1,050,708 | 1,509,782 | 2,159,342 | 1,434,916 | 1,327,242 | 1,186,752 | 2,303,341,000 | 4,463,829,000 | 2,163,000 | 1,796,000 |
| loans | 9,515,801 | 0 | 1,675,964 | 3,274,228 | 4,851,393 | 0 | 0 | 0 | 1,730,074 | 0 | 0 | 0 | 0 | 278,000 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,276,713 | 3,201,566 | 3,076,566,000 | 856,235,000 | 0 | 0 |
| provisions | 0 | 0 | 0 | 27,008 | 62,141 | 35,127 | 34,966 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 9,515,801 | 0 | 1,675,964 | 3,301,236 | 4,913,534 | 35,127 | 34,966 | 0 | 1,730,074 | 2,276,713 | 3,201,566 | 3,076,566,000 | 856,235,000 | 278,000 | 0 |
| total liabilities | 20,218,126 | 17,895,043 | 26,665,028 | 11,551,124 | 13,441,795 | 1,085,835 | 1,544,748 | 2,159,342 | 3,164,990 | 3,603,955 | 4,388,318 | 5,379,907,000 | 5,320,064,000 | 2,441,000 | 1,796,000 |
| net assets | 8,879,852 | 8,041,963 | 7,372,194 | 9,689,006 | 7,640,523 | 6,405,429 | 3,396,219 | 2,888,411 | 1,880,184 | 483,071 | -1,266,803 | -1,718,405,000 | -691,167,000 | 687,000 | 1,040,000 |
| total shareholders funds | 8,879,852 | 8,041,963 | 7,372,194 | 9,689,006 | 7,640,523 | 6,405,429 | 3,396,219 | 2,888,411 | 1,880,184 | 483,071 | -1,266,803 | -1,718,405,000 | -691,167,000 | 687,000 | 1,040,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 2,292,041 | 1,166,176 | -2,416,993 | 2,799,394 | 3,736,541 | 3,064,351 | -1,323,000 | -308,000 | -648,000 | ||||||
| Depreciation | 24,851 | 110,589 | 99,726 | 213,956 | 54,965 | 46,824 | 45,943 | 9,163 | 6,285 | 5,442 | 9,504 | 7,017,000 | 7,000 | 11,000 | 10,000 |
| Amortisation | 666,172 | 696,752 | 594,907 | 591,073 | 92,900 | 7,312 | 6,268 | 6,740 | 44,028 | 60,227 | 149,082 | 225,161,000 | 218,000 | 218,000 | 180,000 |
| Tax | -444,632 | -234,152 | 316,833 | -127,244 | -383,356 | -24,038 | 0 | 0 | 0 | ||||||
| Stock | 1,115,575 | -8,305,614 | 12,635,860 | 3,453,052 | 1,630,780 | 313,178 | -702,988 | 277,278 | 171,521 | 616,777 | 1,530,856 | -1,080,293,000 | 2,889,172,000 | 709,000 | 714,000 |
| Debtors | -1,125,243 | 3,304,981 | -528,635 | -3,027,290 | 4,803,532 | 2,203,185 | 187,939 | -13,950 | 483,424 | 455,746 | 1,082,176 | 342,209,000 | 940,780,000 | -214,000 | 900,000 |
| Creditors | 166,692 | -24,742,584 | 24,753,579 | 139,331 | -58,845 | 61,767 | -21,476 | -180,585 | -1,031,949 | 140,490 | 1,186,752 | -2,160,488,000 | 4,463,571,000 | -274,000 | 532,000 |
| Accruals and Deferred Income | 94,492 | 1,916,339 | -977,684 | 383,062 | -85,013 | 589,496 | -261,909 | 56,761 | 295,287 | 0 | 0 | 0 | -113,000 | 35,000 | 78,000 |
| Deferred Taxes & Provisions | 0 | 0 | -27,008 | -35,133 | 27,014 | 161 | 34,966 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 2,809,284 | -16,086,247 | 10,236,135 | 3,538,677 | -3,050,106 | 1,229,510 | 632,408,000 | -813,000 | -1,462,000 | ||||||
| Investing Activities | |||||||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 0 | -434,000 | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 0 | 0 | 0 | 0 | 0 | -434,000 | |||||||||
| Financing Activities | |||||||||||||||
| Bank loans | -712,117 | 3,645,956 | -1,571,000 | -4,972,414 | 6,543,414 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -6,741,785 | 12,086,268 | -5,465,719 | 4,171,648 | 1,077,997 | -1,110,337 | -216,422 | 698,497 | 844,336 | 0 | 0 | 0 | -1,664,000 | 478,000 | 1,186,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 9,515,801 | -1,675,964 | -1,598,264 | -1,577,165 | 4,851,393 | 0 | 0 | -1,730,074 | 1,730,074 | 0 | 0 | 0 | -278,000 | 278,000 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2,276,713 | -924,853 | 3,201,566 | 2,220,331,000 | 856,235,000 | 0 | 0 |
| share issue | |||||||||||||||
| interest | -1,009,520 | -262,255 | -216,652 | -623,667 | -116,491 | -56,000 | -46,000 | 2,000 | |||||||
| cash flow from financing | 1,052,379 | 13,794,005 | -8,851,635 | -3,001,598 | 12,356,313 | 163,762,000 | 711,000 | 2,887,000 | |||||||
| cash and cash equivalents | |||||||||||||||
| cash | -32,507 | -2,413,931 | 1,340,625 | 231,245 | 863,149 | -127,459 | 125,501 | -261,974 | 349,522 | -81,371 | 92,798 | 67,000 | 0 | -7,000 | 7,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | -149,753 | 149,753 | 0 | 0 | 0 | 0 | -128,000 | 128,000 | 0 |
| change in cash | -32,507 | -2,413,931 | 1,340,625 | 231,245 | 863,149 | -127,459 | 275,254 | -411,727 | 349,522 | -81,371 | 92,798 | 67,000 | 128,000 | -135,000 | 7,000 |
strides pharma uk ltd Credit Report and Business Information
Strides Pharma Uk Ltd Competitor Analysis
Perform a competitor analysis for strides pharma uk ltd by selecting its closest rivals, whether from the MANUFACTURING sector, other large companies, companies in WD18 area or any other competitors across 12 key performance metrics.
strides pharma uk ltd Ownership
STRIDES PHARMA UK LTD group structure
Strides Pharma Uk Ltd has no subsidiary companies.
Ultimate parent company
STRIDES PHARMA SCIENCE LTD
#0097439
2 parents
STRIDES PHARMA UK LTD
02882063
strides pharma uk ltd directors
Strides Pharma Uk Ltd currently has 4 directors. The longest serving directors include Mr Mohana Pillai (Jan 2014) and Mr Visvanathan Rajasekar (Apr 2016).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Mohana Pillai | Singapore | 68 years | Jan 2014 | - | Director |
| Mr Visvanathan Rajasekar | United Kingdom | 63 years | Apr 2016 | - | Director |
| Mahfuzul Islam | United Kingdom | 48 years | Jul 2020 | - | Director |
| Mr Amol Mehta | England | 46 years | May 2022 | - | Director |
P&L
March 2024turnover
28.7m
+17%
operating profit
2.3m
+97%
gross margin
26%
+8.76%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
8.9m
+0.1%
total assets
29.1m
+0.12%
cash
85.6k
-0.28%
net assets
Total assets minus all liabilities
strides pharma uk ltd company details
company number
02882063
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
December 1993
age
31
incorporated
UK
accounts
Full Accounts
ultimate parent company
previous names
strides shasun (uk) ltd (November 2016)
co-pharma limited (February 2016)
last accounts submitted
March 2024
address
unit 4 the metro centre, dwight road, watford, WD18 9SS
accountant
-
auditor
MHA
strides pharma uk ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 8 charges/mortgages relating to strides pharma uk ltd. Currently there are 1 open charges and 7 have been satisfied in the past.
strides pharma uk ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
